Skip to main
VIGL
VIGL logo

Vigil Neuroscience (VIGL) Stock Forecast & Price Target

Vigil Neuroscience (VIGL) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 13%
Hold 38%
Sell 13%
Strong Sell 0%

Bulls say

Vigil Neuroscience Inc is positioned favorably in the biotechnology sector due to its commitment to developing disease-modifying therapeutics targeting neurodegenerative diseases, with VG-3927 demonstrating a promising safety profile and once-daily dosing potential. Biomarker data from the IGNITE study indicates a significant dose-dependent reduction in the TREM2 levels in cerebrospinal fluid, suggesting robust target engagement and supporting the efficacy of iluzanebart in slowing disease progression. Furthermore, the comprehensive approach involving blood/CSF biomarkers and imaging outcomes enhances Vigil's prospects for compelling regulatory filings, reinforcing a positive outlook on its stock performance.

Bears say

Vigil Neuroscience has experienced significant downward pressure on its stock, with shares declining by 26% following the ALEC TREM2 data readout. The company reported a substantial net loss of $23.8 million, translating to a GAAP EPS of $(0.57), which fell short of analyst expectations. Furthermore, the increase in the valuation discount rate to 35% has led to a revised stock target of $13, significantly lower than previous estimates, indicating a challenging financial outlook for the company.

Vigil Neuroscience (VIGL) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 13% recommend Buy, 38% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vigil Neuroscience and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vigil Neuroscience (VIGL) Forecast

Analysts have given Vigil Neuroscience (VIGL) a Buy based on their latest research and market trends.

According to 8 analysts, Vigil Neuroscience (VIGL) has a Buy consensus rating as of Jul 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vigil Neuroscience (VIGL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.